ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia

Cell Reports

Volumn 6, Issue 3, 2014, Pages 528-540

  Weisberg, Stuart P ^a   Smith Raska, Matthew R ^a   Esquilin, Jose M ^a   Zhang, Ji ^b   Arenzana, Teresita L ^a   Lau, Colleen M ^a   Churchill, Michael ^a   Pan, Haiyan ^a   Klinakis, Apostolos ^c   Dixon, Jack E ^b   Mirny, Leonid A ^d   Mukherjee, Siddhartha ^a   Reizis, Boris ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; ISOCITRATE DEHYDROGENASE 2; MA9 PROTEIN; MITOCHONDRIAL ENZYME; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; NOTCH1 RECEPTOR; PTPMT1 PROTEIN; REGULATOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZFX; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE T LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CELL LINEAGE; CELL MATURATION; CELL RENEWAL; CONTROLLED STUDY; DISEASE COURSE; DNA MODIFICATION; GENE ACTIVATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; HEMATOPOIETIC STEM CELL; IDH2 GENE; LEUKEMOGENESIS; MOUSE; MYELOID LEUKEMIA; MYELOID PROGENITOR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PTPMT1 GENE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; GENE EXPRESSION REGULATION, LEUKEMIC; ISOCITRATE DEHYDROGENASE; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKEMIA, MYELOID, ACUTE; MICE; MITOCHONDRIA; PHENOTYPE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; RECEPTORS, NOTCH;

EID: 84893830966     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.01.007     Document Type: Article

References (45)

1. Alam M.S., Maekawa Y., Kitamura A., Tanigaki K., Yoshimoto T., Kishihara K., Yasutomo K. Notch signaling drives IL-22 secretion in CD4+ Tcells by stimulating the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. USA 2010, 107:5943-5948.
2. Ayton P.M., Cleary M.L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003, 17:2298-2307.
3. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
4. Buonamici S., Trimarchi T., Ruocco M.G., Reavie L., Cathelin S., Mar B.G., Klinakis A., Lukyanov Y., Tseng J.C., Sen F., et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009, 459:1000-1004.
5. Chen X., Xu H., Yuan P., Fang F., Huss M., Vega V.B., Wong E., Orlov Y.L., Zhang W., Jiang J., et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008, 133:1106-1117.
6. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., Metzeler K.H., Poeppl A., Ling V., Beyene J., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 2011, 17:1086-1093.
7. Galan-Caridad J.M., Harel S., Arenzana T.L., Hou Z.E., Doetsch F.K., Mirny L.A., Reizis B. Zfx controls the self-renewal of embryonic and hematopoietic stem cells. Cell 2007, 129:345-357.
8. Harel S., Tu E.Y., Weisberg S., Esquilin M., Chambers S.M., Liu B., Carson C.T., Studer L., Reizis B., Tomishima M.J. ZFX controls the self-renewal of human embryonic stem cells. PLoS ONE 2012, 7:e42302.
9. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
10. Jude C.D., Climer L., Xu D., Artinger E., Fisher J.K., Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007, 1:324-337.
11. Kim J., Woo A.J., Chu J., Snow J.W., Fujiwara Y., Kim C.G., Cantor A.B., Orkin S.H. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010, 143:313-324.
12. King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Ntziachristos P., Aranda-Orgilles B., Perez-Garcia A., Shi J., Vakoc C., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153:1552-1566.
13. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
14. Kroon E., Krosl J., Thorsteinsdottir U., Baban S., Buchberg A.M., Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998, 17:3714-3725.
15. Li X., Gounari F., Protopopov A., Khazaie K., von Boehmer H. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J.Exp. Med. 2008, 205:2851-2861.
16. Liedtke M., Cleary M.L. Therapeutic targeting of MLL. Blood 2009, 113:6061-6068.
17. Lin C.Y., Lovén J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
18. Luo H., Li Q., O'Neal J., Kreisel F., Le Beau M.M., Tomasson M.H. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 2005, 106:2452-2461.
19. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
20. McMahon K.A., Hiew S.Y., Hadjur S., Veiga-Fernandes H., Menzel U., Price A.J., Kioussis D., Williams O., Brady H.J. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 2007, 1:338-345.
21. Muntean A.G., Tan J., Sitwala K., Huang Y., Bronstein J., Connelly J.A., Basrur V., Elenitoba-Johnson K.S., Hess J.L. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010, 17:609-621.
22. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., Wang R., Green D.R., Tessarollo L., Casellas R., et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
23. Niemi N.M., Lanning N.J., Westrate L.M., MacKeigan J.P. Downregulation of the mitochondrial phosphatase PTPMT1 is sufficient to promote cancer cell death. PLoS ONE 2013, 8:e53803.
24. O'Donnell K.A., Keng V.W., York B., Reineke E.L., Seo D., Fan D., Silverstein K.A., Schrum C.T., Xie W.R., Mularoni L., et al. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc. Natl. Acad. Sci. USA 2012, 109:E1377-E1386.
25. Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., Barnes K.C., O'Neil J., Neuberg D., Weng A.P., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 2006, 103:18261-18266.
26. Pui J.C., Allman D., Xu L., DeRocco S., Karnell F.G., Bakkour S., Lee J.Y., Kadesch T., Hardy R.R., Aster J.C., Pear W.S. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999, 11:299-308.
27. Radtke F., Wilson A., Stark G., Bauer M., van Meerwijk J., MacDonald H.R., Aguet M. Deficient Tcell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10:547-558.
28. Schreiner S., Birke M., García-Cuéllar M.P., Zilles O., Greil J., Slany R.K. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res. 2001, 61:6480-6486.
29. Smith L.L., Yeung J., Zeisig B.B., Popov N., Huijbers I., Barnes J., Wilson A.J., Taskesen E., Delwel R., Gil J., et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011, 8:649-662.
30. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
31. Somervaille T.C., Matheny C.J., Spencer G.J., Iwasaki M., Rinn J.L., Witten D.M., Chang H.Y., Shurtleff S.A., Downing J.R., Cleary M.L. Hierarchical maintenance of MLL myeloid leukemia stem cells employs atranscriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009, 4:129-140.
32. Sykes S.M., Lane S.W., Bullinger L., Kalaitzidis D., Yusuf R., Saez B., Ferraro F., Mercier F., Singh H., Brumme K.M., et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011, 146:697-708.
33. Wang Q.F., Wu G., Mi S., He F., Wu J., Dong J., Luo R.T., Mattison R., Kaberlein J.J., Prabhakar S., et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011, 117:6895-6905.
34. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
35. Wendorff A.A., Koch U., Wunderlich F.T., Wirth S., Dubey C., Brüning J.C., MacDonald H.R., Radtke F. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity 2010, 33:671-684.
36. Weng A.P., Ferrando A.A., Lee W., Morris J.P., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human Tcell acute lymphoblastic leukemia. Science 2004, 306:269-271.
37. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., Del Bianco C., Rodriguez C.G., Sai H., Tobias J., et al. c-Myc is animportant direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006, 20:2096-2109.
38. Wise D.R., Ward P.S., Shay J.E., Cross J.R., Gruber J.J., Sachdeva U.M., Platt J.M., DeMatteo R.G., Simon M.C., Thompson C.B. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 2011, 108:19611-19616.
39. Wolfer A., Bakker T., Wilson A., Nicolas M., Ioannidis V., Littman D.R., Lee P.P., Wilson C.B., Held W., MacDonald H.R., Radtke F. Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat. Immunol. 2001, 2:235-241.
40. Wong P., Iwasaki M., Somervaille T.C., So C.W., Cleary M.L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007, 21:2762-2774.
41. Wong P., Iwasaki M., Somervaille T.C., Ficara F., Carico C., Arnold C., Chen C.Z., Cleary M.L. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 2010, 70:3833-3842.
42. Yu W.M., Liu X., Shen J., Jovanovic O., Pohl E.E., Gerson S.L., Finkel T., Broxmeyer H.E., Qu C.K. Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation. Cell Stem Cell 2013, 12:62-74.
43. Zhang J., Guan Z., Murphy A.N., Wiley S.E., Perkins G.A., Worby C.A., Engel J.L., Heacock P., Nguyen O.K., Wang J.H., et al. Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. Cell Metab. 2011, 13:690-700.
44. Zuber J., Rappaport A.R., Luo W., Wang E., Chen C., Vaseva A.V., Shi J., Weissmueller S., Fellmann C., Taylor M.J., et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011, 25:1628-1640.
45. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.